MTOR and malignant colon neoplasm: Variable proportions of breast, ovarian, prostate, and colon cancer cells express signaling proficient NKG2D–DAP10 complexes, which activate the PI3K-AKT-mTOR (mammalian target of rapamycin) signaling axis and downstream effectors.